KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Effects of taurine supplementation on metabolic health and biological aging in healthcare workers: A protocol for a triple-blinded, Bayesian-optimized phase II randomized controlled trial. PMID 42201902 · PLoS One · 2026 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Mixed-Method Formative Evaluation and Cultural Adaptation of Digital Health Communication Content and Delivery Promoting Lung Cancer Screening Shared Decision-Making. PMID 42201308 · Cancer Control · 2026 Eligibility excluded because the study lacks a drug-containing intervention and does not report a time-to-event efficacy endpoint. It is a formative evaluation of a digital health communication tool for lung cancer screening shared decision-making, not a randomized trial of a therapeutic drug with survival or progression outcomes.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Moxibustion for gastrointestinal cancer-related fatigue: study protocol for a randomized clinical trial. PMID 42199916 · Front Psychiatry · 2026 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Telmisartan 20 mg/S-Amlodipine 2.5 mg versus Telmisartan 40 mg in Patients with Hypertension, Inadequately Controlled on Telmisartan 20 mg Monotherapy: A Randomized, Double-Blind, Multicenter, Phase 3 Trial. PMID 42199811 · Drug Des Devel Ther · 2026 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Sequential versus concurrent neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell carcinoma: a randomized, controlled, open-label, phase 2 trial (HCHTOG1906). PMID 42183251 · Front Immunol · 2026 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
TROPION-Lung14 study protocol: a phase III study of osimertinib in combination with datopotamab deruxtecan versus osimertinib alone as first-line treatment for patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer. PMID 42182601 · Ther Adv Med Oncol · 2026 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Comparative Effectiveness of Cytisinicline and Varenicline for Smoking Cessation: A Matching-Adjusted Indirect Comparison (MAIC). PMID 42180667 · J Health Econ Outcomes Res · 2026 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and safety of first-line osimertinib monotherapy versus osimertinib plus platinum-based chemotherapy or amivantamab plus lazertinib in metastatic EGFR-mutated NSCLC: an indirect comparison. PMID 42180117 · Front Oncol · 2026 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 3 Figure · 6 Panel · risk visible
Timely Integration of specialist palliative care into oncology care for patients receiving radiotherapy for bone metastases: A study procotol for the TIPZO-RT Randomized Controlled Trial. PMID 42172282 · PLoS One · 2026 This is a protocol for a randomized trial evaluating a non-drug palliative care intervention with a primary endpoint of patient satisfaction. It lacks original results, does not involve a drug intervention, and does not have a primary time-to-event efficacy endpoint (OS, PFS, etc.).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Design of the MERCURION-IPF trial - intravenous immunoglobulin for the treatment of acute exacerbations of idiopathic pulmonary fibrosis. PMID 42164489 · Front Immunol · 2026 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Fimasartan/Indapamide Combination Therapy versus Fimasartan Monotherapy in Patients with Essential Hypertension Inadequately Responding to Fimasartan 30 mg (FINEDUO): A Randomized, Double-Blind, Multicenter, Phase III Study. PMID 42163997 · Drug Des Devel Ther · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H L
旧查询独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Carcinoembryonic Antigen Flare Under Oxaliplatin-Based Chemotherapy Predicts Benefit from Nivolumab in Metastatic Microsatellite-Stable Colorectal Cancer - A Post Hoc Analysis of METIMMOX Trial Data. PMID 42158080 · Immunotargets Ther · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Sports-based mental health promotion for adolescents in rural Nepal: A pilot cluster-randomised controlled trial. PMID 42149858 · PLOS Glob Public Health · 2026 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Co-creation of a mobile health program (MumCare) for preventing maternal cardiovascular disease after pregnancy complications. PMID 42145904 · Front Glob Womens Health · 2026 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Twenty-year results of the randomized European Organization for Research and Treatment of Cancer trial 22922/10925 evaluating internal mammary chain and medial supraclavicular lymph node irradiation in stage I-III breast cancer. PMID 42141924 · CA Cancer J Clin · 2026 The study is a randomized, oncology trial with time-to-event endpoints, but it evaluates a radiotherapy intervention (internal mammary and medial supraclavicular lymph node irradiation) and does not involve a drug-containing intervention arm, which is required for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Correction to "Tegoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Phase III Multicenter Randomized Clinical Trial". PMID 42141840 · Helicobacter · 2026 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Preventive effect of transcutaneous electrical acupoint stimulation pretreatment on lymphedema in patients undergoing axillary lymph node dissection for breast cancer: a randomized controlled trial protocol. PMID 42137144 · Front Oncol · 2026 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Pattern of resistance on first-line EGFR-directed therapy in EGFR-positive metastatic NSCLC. PMID 42131879 · Ecancermedicalscience · 2026 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Phase III, randomized, single blind, comparative safety, and efficacy trial of intravenous iron isomaltoside (i3R) and ferric carboxy maltose in subjects with iron deficiency anaemia. PMID 42111869 · Med J Armed Forces India · 2026 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy of immunotherapy and targeted therapy for unresectable hepatocellular carcinoma: analysis of survival curves. PMID 42110472 · Front Med (Lausanne) · 2026 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 2 Figure · 5 Panel · risk not_visible
Cost-utility and price threshold analysis of sacituzumab tirumotecan versus single-agent chemotherapy for previously treated metastatic triple-negative breast cancer in China. PMID 42110256 · Front Public Health · 2026 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy and Descriptive Safety Assessment of Programmed Cell Death Protein-(Ligand) 1 Inhibitors Plus Chemotherapy as First-Line Treatment for Gastric and Gastroesophageal Junction Cancer in Asian and Non-Asian Patients: A Meta-Analysis. PMID 42109272 · Gastro Hep Adv · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
The therapeutic potential of epimedium and its bioactive flavonoids in hepatitis and cirrhosis: an integrative review. PMID 42100655 · Front Cell Infect Microbiol · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Personalized swallowing rehabilitation program for post-surgical dysphagia in oral cancer patients: a randomized controlled trial. PMID 42100422 · Front Oncol · 2026 The study is a randomized controlled trial in oral cancer patients evaluating a non-drug rehabilitation intervention with functional (FOIS) and patient-reported (MDADI) outcomes. It lacks a drug-containing intervention and a primary/key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Favorable safety outcomes of a perioperative propranolol and etodolac regimen in cancer patients in four randomized controlled trials. PMID 42088573 · Front Pharmacol · 2026 The report is a safety-focused analysis of four RCTs, with efficacy outcomes (DFS, OS) presented as secondary/exploratory endpoints. The trial phase is not explicitly stated, and the primary purpose is to evaluate safety, not to present formal efficacy results from a definitive Phase III or equivalent trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Brief report: Artificial intelligence meets small cell lung cancer-integrating clinicopathological and wholeslide image data for prognostic prediction in SCLC. PMID 42088381 · Front Artif Intell · 2026 This is a secondary analysis of data from the phase IIIB CANTABRICO trial to validate an AI-based prognostic model. While it involves a phase III trial and time-to-event endpoints, the report itself does not present the primary efficacy results of a drug-containing intervention from a randomized trial. It is a predictive biomarker/model validation study.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
RNI Precision Trial Protocol: Optimization of Regional Node Irradiation for Sentinel Lymph Node-positive Breast Cancer Omitting Axillary Dissection Based on Clinical and Genomic Risk Assessment: A Prospective Clinical Trial. PMID 42081886 · Technol Cancer Res Treat · 2026 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Efficacy and safety of first-line therapies for persistent, recurrent, or metastatic cervical cancer: a systematic review and exploratory network meta-analysis of immunotherapy. PMID 42079658 · Front Immunol · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Linzagolix, with and without add-back therapy, in women with endometriosis-associated pain: results from EDELWEISS 6, a double-blind randomized extension and withdrawal study. PMID 42077502 · Hum Reprod Open · 2026 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
The Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer. PMID 42065071 · Oncol Res · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: A Meta-Analysis of All Randomized Clinical Trials with Subgroup Analysis by Patient Profile. PMID 42065038 · Oncol Res · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Efficacy and safety of transcutaneous electrical acupoint stimulation and acupressure in alleviating chemotherapy-related adverse reactions in female patients with breast cancer: a randomized clinical trial. PMID 42063721 · Front Oncol · 2026 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
KRASG12C inhibitors versus chemotherapy alone for KRASG12C-mutated non-small cell lung cancer: a pooled analysis of CodeBreaK 200 and KRYSTAL-12 trials. PMID 42063697 · Front Oncol · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Effects of mindfulness yoga intervention on physical function, anxiety, inflammatory response, and relapse intention in methamphetamine addicts: a 24-week randomized controlled trial. PMID 42058068 · Front Public Health · 2026 The study is a randomized controlled trial but is not an oncology trial. It investigates a non-drug (yoga/mindfulness) intervention for methamphetamine addiction and does not involve a human malignant neoplasm. There is no drug intervention and no primary/key secondary time-to-event efficacy endpoint (like OS, PFS, DFS, etc.) relevant to oncology Kaplan-Meier digitization.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effects of total intravenous anesthesia on postoperative quality of recovery and the levels of inflammatory factors in patients undergoing retroperitoneal endoscopic surgery in urology: Study protocol for a randomized, controlled trial. PMID 42054415 · PLoS One · 2026 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Effects of lemborexant and zolpidem on sleep electroencephalography in older adults with insomnia: a randomized trial. PMID 42052562 · Sleep Adv · 2026 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Brexpiprazole for Agitation in Patients with Alzheimer's Dementia with and without Co-Occurring Psychosis: Post Hoc Analysis of Short- and Long-Term Trials. PMID 42052145 · Neuropsychiatr Dis Treat · 2026 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
CALGB 140503 and the shift to sublobar resection for small, peripheral, node-negative NSCLC: historical context, secondary analyses, and next steps. PMID 42038383 · Front Oncol · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
De-escalation of head-and-neck cancer radiotherapy: balancing cure and side effects. PMID 42038372 · Front Oncol · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Clinical efficacy of comprehensive traditional Chinese medicine in adjuvant therapy for stage Ib-IIIa resected non-small cell lung cancer: a multi-center, randomized, double-blind, placebo-controlled trial. PMID 42038290 · Front Pharmacol · 2026 The record fails the 'phase3_or_definitive' criterion because the trial phase is not explicitly established in the provided metadata. While it is a definitive-sized randomized trial (n=286) with a time-to-event endpoint, the criteria require explicit evidence of a Phase III/IIIb or Phase II/III designation, which is absent.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effects of Oxycodone versus Sufentanil-Based Intravenous Patient-Controlled Multimodal Analgesia on Early Gastrointestinal Recovery and Pain After Laparoscopic Colorectal Cancer Surgery: A Randomized Double-Blind Trial. PMID 42005586 · J Pain Res · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Preservative-Free Bimatoprost 0.01% Gel in Patients with Open-Angle Glaucoma and Ocular Hypertension: Results from Two Phase III Randomized Trials. PMID 42004641 · Clin Ophthalmol · 2026 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Unguided web-based brief intervention with genetic risk education to reduce unhealthy alcohol consumption in Japan: Protocol for a randomized controlled trial. PMID 41996377 · PLoS One · 2026 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Bayesian reanalysis of early remdesivir for the treatment of COVID-19 in outpatients with high risk of progression to severe disease. PMID 41990093 · PLoS One · 2026 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Remimazolam versus propofol for postoperative ICU sedation in mechanically ventilated cancer patients: a noninferiority randomized clinical trial. PMID 41988528 · Front Pharmacol · 2026 The study is an oncology-related randomized trial with a drug intervention and original results. However, it is excluded because it lacks a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, TTP, Kaplan-Meier, HR). The primary outcomes are pharmacodynamic (time to achieve sedation, percentage of time in sedation range), and secondary outcomes include mortality but without time-to-event analysis reported. The phase is not explicitly stated, and the trial is not identified as a definitive Phase III/IIIb or II/III trial. Therefore, it does not meet the criteria for inclusion in this cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Nutritional prehabilitation in head and neck cancer patients (PreHead) - A randomized controlled trial study protocol. PMID 41984990 · PLoS One · 2026 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Effect of Prehabilitation-Based Individualized Dietary Guidance on Nutrition and Short-Term Quality of Life in Locally Advanced Gastric Cancer Patients Undergoing Surgery: A Single-Center Randomized Controlled Trial. PMID 41969312 · J Multidiscip Healthc · 2026 The record describes a randomized trial in oncology patients (locally advanced gastric cancer) but does not meet key eligibility criteria. It is not a drug-intervention study; the intervention is 'individualized dietary guidance based on the prehabilitation concept'. It does not report a primary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). Endpoints are nutritional outcomes, quality of life, and postoperative safety. The trial phase is not specified as definitive (Phase III/IIIb or Phase II/III). Therefore, it is excluded.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Tirzepatide in Metabolically Dysfunctional-Associated Steatohepatitis (MASH): A Bibliometric and Evidence-Based Review. PMID 41964153 · J Diabetes Res · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Evolving therapeutic pipeline for tumor-infiltrating lymphocytes in metastatic melanoma - a review. PMID 41958653 · Front Immunol · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Repeated lower extremities hot water bathing (REHAB), a rehabilitative strategy in Parkinson's disease (PD) patients with sleep disorders: rationale, design and protocol for a randomized controlled study. PMID 41952857 · Front Neurol · 2026 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -